AstraZeneca PLC (AZN) Announces New Safety Data For Naloxegol In Patients With Opioid-Induced Constipation
10/14/2013 9:47:19 AM
SAN DIEGO--(BUSINESS WIRE)--AstraZeneca (NYSE: AZN) today announced the results of a Phase III long-term safety and tolerability study of the once-daily 25mg dose of naloxegol, in patients with non-cancer pain and opioid-induced constipation (OIC). Naloxegol is an investigational peripherally-acting mu-opioid receptor antagonist (PAMORA), which has been studied in OIC in adult patients with chronic non-cancer pain, a common condition caused by prescription opioid pain medicines. Data were presented at the American College of Gastroenterology (ACG) 2013 Annual Scientific Meeting in San Diego, California.
Help employers find you! Check out all the jobs and post your resume.
comments powered by